THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO
596/2014
Verona Pharma
Plans to Conduct Registered Initial Public Offering in the U.S.
November 23, 2016, Cardiff
– Verona Pharma plc (AIM: VRP) today announced that it plans to
conduct a registered initial public offering in the United States. The number of shares and
price of the proposed offering have not yet been determined. The
proposed offering is expected to commence in the first half of
2017, after the U.S. Securities and Exchange Commission completes
its review process of the registration statement relating to the
proposed offering and subject to market and other conditions.
This press release is being made pursuant to and in accordance
with Rule 135 under the Securities Act of 1933, as amended. This
press release does not constitute an offer to sell or the
solicitation of an offer to buy securities, and shall not
constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of that
jurisdiction.
Forward Looking Statements
This press release contains forward-looking statements. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements, including without limitation statements regarding our
plans to conduct a registered initial public offering in
the United States and the timing
of the proposed offering.
These forward-looking statements are based on management’s
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from our
expectations expressed or implied by the forward-looking
statements, including, but not limited to, the following: we may
determine not to conduct a registered initial public offering in
the time frame that we currently expect or at all, due to a number
of potential important factors, including conditions in the U.S.
capital markets, negative global economic conditions, potential
negative developments in our clinical trials or research programs,
other negative developments in our business, or unfavorable
legislative or regulatory developments.
These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management’s estimates as of the date of this
press release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
-Ends-
For further information please
contact:
Verona Pharma plc |
Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive
Officer |
|
|
|
N+1 Singer |
Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer |
|
|
|
FTI Consulting |
Tel: +44 (0)20 3727 1000 |
Simon Conway /
Stephanie Cuthbert /
Natalie Garland-Collins |
|